These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31130605)

  • 1. Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide.
    Yang B; Lin SJ; Ren JY; Liu T; Wang YM; Li CM; Xu WW; He YW; Zheng WH; Zhao J; Yuan XH; Liao HX
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis.
    Yokoo T; Tanabe A; Yoshida Y; Caaveiro JMM; Nakakido M; Ikeda Y; Fujimura Y; Matsumoto M; Entzminger K; Maruyama T; Okumura CJ; Nangaku M; Tsumoto K
    J Biol Chem; 2022 Jun; 298(6):101962. PubMed ID: 35452676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization of Two Monoclonal Antibodies against the Same Epitope on B-Cell Receptor Associated Protein 31.
    Kim WT; Shin S; Hwang HJ; Kim MK; Jung HS; Park H; Ryu CJ
    PLoS One; 2016; 11(12):e0167527. PubMed ID: 27907150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.
    Bushey RT; Moody MA; Nicely NL; Haynes BF; Alam SM; Keir ST; Bentley RC; Roy Choudhury K; Gottlin EB; Campa MJ; Liao HX; Patz EF
    Cell Rep; 2016 May; 15(7):1505-1513. PubMed ID: 27160908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
    Bhattacharjee A; Reuter S; Trojnár E; Kolodziejczyk R; Seeberger H; Hyvärinen S; Uzonyi B; Szilágyi Á; Prohászka Z; Goldman A; Józsi M; Jokiranta TS
    J Biol Chem; 2015 Apr; 290(15):9500-10. PubMed ID: 25659429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the respective loops at complementarity determining region on the antigen-antibody recognition.
    Osajima T; Hoshino T
    Comput Biol Chem; 2016 Oct; 64():368-383. PubMed ID: 27591792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
    Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
    J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Tools for Aiding Rational Antibody Design.
    Krawczyk K; Dunbar J; Deane CM
    Methods Mol Biol; 2017; 1529():399-416. PubMed ID: 27914064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions.
    Dekker LJ; Zeneyedpour L; Brouwer E; van Duijn MM; Sillevis Smitt PA; Luider TM
    Anal Bioanal Chem; 2011 Jan; 399(3):1081-91. PubMed ID: 21107826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes.
    Robin G; Sato Y; Desplancq D; Rochel N; Weiss E; Martineau P
    J Mol Biol; 2014 Nov; 426(22):3729-3743. PubMed ID: 25174334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
    Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
    Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation.
    Zhang D; Chen CF; Zhao BB; Gong LL; Jin WJ; Liu JJ; Wang JF; Wang TT; Yuan XH; He YW
    PLoS One; 2013; 8(11):e80636. PubMed ID: 24278299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A computational approach for studying antibody-antigen interactions without prior structural information: the anti-testosterone binding antibody as a case study.
    Koivuniemi A; Takkinen K; Nevanen T
    Proteins; 2017 Feb; 85(2):322-331. PubMed ID: 27936519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational and statistical study on the molecular interaction between antigen and antibody.
    Osajima T; Suzuki M; Neya S; Hoshino T
    J Mol Graph Model; 2014 Sep; 53():128-139. PubMed ID: 25123651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics.
    Van Holsbeeck K; Martins JC; Ballet S
    Bioorg Chem; 2022 Feb; 119():105563. PubMed ID: 34942468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.
    Pintér C; Siccardi AG; Lopalco L; Longhi R; Clivio A
    AIDS Res Hum Retroviruses; 1995 Aug; 11(8):971-80. PubMed ID: 7492444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen type II is recognized by a pathogenic antibody through germline encoded structures.
    Böiers U; Lanig H; Sehnert B; Holmdahl R; Burkhardt H
    Eur J Immunol; 2008 Oct; 38(10):2784-95. PubMed ID: 18825755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.
    Campa MJ; Gottlin EB; Bushey RT; Patz EF
    Cancer Immunol Res; 2015 Dec; 3(12):1325-32. PubMed ID: 26216416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward rational antibody design: recent advancements in molecular dynamics simulations.
    Yamashita T
    Int Immunol; 2018 Apr; 30(4):133-140. PubMed ID: 29346652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.